@entity786 (3.6 g/m2) therapy with @entity1261 support for resistant XXXX .

@entity1 @entity632 @entity137 @entity712 @entity1261 @entity55 @entity229 @entity786 @entity3601 @entity1582
BACKGROUND: In @entity1582 @entity1 resistance to both @entity3601 - and @entity632 -containing regimens has been related to very short survival (approximately 6 months). The development of effective regimens combined with a low @entity137 rate is mandatory in this @entity1 subgroup. METHODS: Fourteen resistant @entity1582 @entity1 were treated with @entity786 (a total of 3.6 g/m2 was delivered in 2 doses on days 1 and 3) and @entity229 (2 mg/kg, days 1-4) every month for 4 cycles. @entity1261 support was administered to reduce myelosuppression. RESULTS: This combination was well tolerated. Granulocyte levels fell below 0.1 x 10(9)/L in all @entity1 after a median of 9 days (range 8-11), followed by recovery to 0.5 x 10(9)/L after a median of 12 days from the start of treatment (range 10-13 days). Platelets never fell below 50 x 10(9)/L. All @entity1 were treated on an outpatient basis and only 2 required hospitalization for major complications ( @entity55 and @entity712 ). Response to @entity786 was observed in 6/14 @entity1 : 2 achieved complete remission, 4 showed a 50% or greater reduction of the M-component. Five @entity1 are still in remission after 2, 6, 7, 9 and 10 months; 1 relapsed after 10 months. All @entity1 except one are alive 4-16 months from the start of treatment. CONCLUSIONS: This schedule may represent a new approach for resistant @entity1582 , and its very low @entity137 allows it to be delivered on an outpatient basis.
